642 related articles for article (PubMed ID: 26382603)
21. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.
Gambhira R; Jagu S; Karanam B; Gravitt PE; Culp TD; Christensen ND; Roden RB
J Virol; 2007 Nov; 81(21):11585-92. PubMed ID: 17715230
[TBL] [Abstract][Full Text] [Related]
22. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
[TBL] [Abstract][Full Text] [Related]
23. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.
Jagu S; Kwak K; Garcea RL; Roden RB
Vaccine; 2010 Jun; 28(28):4478-86. PubMed ID: 20434552
[TBL] [Abstract][Full Text] [Related]
24. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses.
Seitz H; Canali E; Ribeiro-Müller L; Pàlfi A; Bolchi A; Tommasino M; Ottonello S; Müller M
Vaccine; 2014 May; 32(22):2610-7. PubMed ID: 24662712
[TBL] [Abstract][Full Text] [Related]
25. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
[TBL] [Abstract][Full Text] [Related]
26. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.
Schellenbacher C; Huber B; Skoll M; Shafti-Keramat S; Roden RBS; Kirnbauer R
Vaccine; 2019 Jun; 37(27):3529-3534. PubMed ID: 31147274
[TBL] [Abstract][Full Text] [Related]
27. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
Tumban E; Peabody J; Peabody DS; Chackerian B
PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
[TBL] [Abstract][Full Text] [Related]
28. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
29. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
Schellenbacher C; Roden R; Kirnbauer R
J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
[TBL] [Abstract][Full Text] [Related]
30. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
[TBL] [Abstract][Full Text] [Related]
31. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
[TBL] [Abstract][Full Text] [Related]
32. A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.
Motavalli Khiavi F; Arashkia A; Golkar M; Nasimi M; Roohvand F; Azadmanesh K
J Immunol Res; 2018; 2018():9464186. PubMed ID: 29854852
[No Abstract] [Full Text] [Related]
33. A human papillomavirus type 16 vaccine by oral delivery of L1 protein.
Sasagawa T; Tani M; Basha W; Rose RC; Tohda H; Giga-Hama Y; Azar KK; Yasuda H; Sakai A; Inoue M
Virus Res; 2005 Jun; 110(1-2):81-90. PubMed ID: 15845258
[TBL] [Abstract][Full Text] [Related]
34. A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types.
Chen X; Liu H; Zhang T; Liu Y; Xie X; Wang Z; Xu X
PLoS One; 2014; 9(5):e95448. PubMed ID: 24802101
[TBL] [Abstract][Full Text] [Related]
35. Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes.
Palmer KE; Benko A; Doucette SA; Cameron TI; Foster T; Hanley KM; McCormick AA; McCulloch M; Pogue GP; Smith ML; Christensen ND
Vaccine; 2006 Jun; 24(26):5516-25. PubMed ID: 16725236
[TBL] [Abstract][Full Text] [Related]
36. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
Giannini SL; Hanon E; Moris P; Van Mechelen M; Morel S; Dessy F; Fourneau MA; Colau B; Suzich J; Losonksy G; Martin MT; Dubin G; Wettendorff MA
Vaccine; 2006 Aug; 24(33-34):5937-49. PubMed ID: 16828940
[TBL] [Abstract][Full Text] [Related]
37. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
38. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
39. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.
Fraillery D; Zosso N; Nardelli-Haefliger D
Vaccine; 2009 Apr; 27(17):2326-34. PubMed ID: 19428847
[TBL] [Abstract][Full Text] [Related]
40. Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine.
Seitz H; Ribeiro-Müller L; Canali E; Bolchi A; Tommasino M; Ottonello S; Müller M
Cancer Prev Res (Phila); 2015 Oct; 8(10):932-41. PubMed ID: 26170394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]